2. Apoptosis
  3. Apoptosis MDM-2/p53
  4. Kevetrin

Kevetrin  (Synonyms: 3-Cyanopropyl carbamimidothioate; 4-Isothioureidobutyronitrile)

Cat. No.: HY-16270
Handling Instructions Technical Support

Kevetrin (3-Cyanopropyl carbamimidothioate; 4-Isothioureidobutyronitrile) is an apoptosis inducer that exhibits p53-dependent and p53-independent antitumor activity. In TP53 wild-type models, Kevetrin activates and stabilizes the p53 protein by altering the processing of MDM2, thereby inducing cell cycle arrest and apoptosis. Kevetrin shows higher sensitivity in mutant models. Kevetrin is applicable for the research of various cancers including acute myeloid leukemia and breast cancer.

For research use only. We do not sell to patients.

Kevetrin

Kevetrin Chemical Structure

CAS No. : 500863-50-3

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other In-stock Forms of Kevetrin:

Other Forms of Kevetrin:

Kevetrin Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Kevetrin (3-Cyanopropyl carbamimidothioate; 4-Isothioureidobutyronitrile) is an apoptosis inducer that exhibits p53-dependent and p53-independent antitumor activity. In TP53 wild-type models, Kevetrin activates and stabilizes the p53 protein by altering the processing of MDM2, thereby inducing cell cycle arrest and apoptosis. Kevetrin shows higher sensitivity in mutant models. Kevetrin is applicable for the research of various cancers including acute myeloid leukemia and breast cancer[1].

In Vitro

Kevetrin (85-340 μM; 6-72 h) does not reduce the viability of TP53 wild-type MOLM-13 acute myeloid leukemia (AML) cells, nor does it induce significant apoptosis in these cells[1].
Kevetrin (85-340 μM; 6-72 h) reduces cell viability and induces apoptosis in TP53-mutant KASUMI-1 acute myeloid leukemia (AML) cells in a dose- and time-dependent manner, with more significant efficacy after repeated administration cycles[1].
Kevetrin (340 μM; 6 h) alters the expression of MT family genes and several leukemia-related transcriptional regulators in TP53 wild-type MOLM-13 cells and TP53 mutant KASUMI-1 acute myeloid leukemia (AML) cells[1].
Kevetrin (85-340 μM; 48 h) reduces cell viability in both TP53 wild-type and TP53 mutant AML cell lines, with TP53 mutant cell lines exhibiting higher sensitivity[1].
Kevetrin (85-340 μM; 24-48 h) induces apoptosis in both TP53 wild-type and TP53 mutant acute myeloid leukemia (AML) cell lines, with TP53 mutant cell lines exhibiting a stronger, dose-dependent apoptotic response[1].
Kevetrin (85, 170, 340 μM; 24-48 h) induces G0/G1 cell cycle arrest in TP53 wild-type OCI-AML3 cells and TP53-mutant NOMO-1 acute myeloid leukemia (AML) cells, but does not alter the cell cycle progression of TP53 wild-type MOLM-13 cells or TP53-mutant KASUMI-1 AML cells[1].
Kevetrin (85-340 μM; 48 h) reduces the viability of primary AML cells and induces their apoptosis, exhibits selective cytotoxic activity against blasts, and shows higher sensitivity in primary samples with TP53 mutations[1].
Kevetrin (340 μM; 48 h) alters a shared core transcriptional program in TP53 wild-type MOLM-13 and TP53-mutant KASUMI-1 acute myeloid leukemia (AML) cells, downregulates key oncogenic pathways such as glycolysis and DNA repair, and upregulates p53 target genes and p53 pathway-associated transcriptional signatures[1].
Kevetrin (85-340 μM; 48 h) upregulates p21 in a dose-dependent manner in TP53 wild-type AML cells, increases the expression level of p53 and promotes its nuclear localization, and also induces the accumulation of p53 in apoptotic cells, with a stronger induction effect of p53 in TP53-mutant AML cell lines[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Kevetrin Related Antibodies

Cell Viability Assay[1]

Cell Line: TP53-wild-type OCI-AML3, MOLM-13, and TP53-mutant KASUMI-1, NOMO-1 acute myeloid leukemia (AML) cell lines
Concentration: 85, 170, 340 μM
Incubation Time: 24 h; 48 h
Result: Barely altered cell viability across all cell lines after 24 h treatment.
Significantly reduced viability in MOLM-13 cells at 340 μM, in OCI-AML3 cells at 170 and 340 μM, and in KASUMI-1 and NOMO-1 cells in a dose-dependent manner at all tested concentrations after 48 h treatment.

Apoptosis Analysis[1]

Cell Line: TP53-wild-type OCI-AML3, MOLM-13, and TP53-mutant KASUMI-1, NOMO-1 acute myeloid leukemia (AML) cell lines
Concentration: 85, 170, 340 μM (24 h; 48 h)
Incubation Time: 24 h; 48 h
Result: Induced significant apoptosis (Annexin V+ cells) in KASUMI-1 cells at 340 μM after 24 h treatment.
Increased Annexin V+ cells to 54.95 ± 5.63% in MOLM-13 cells at 340 μM, 10.03 ± 3.79% in OCI-AML3 cells at 340 μM, 79.70 ± 4.57% in KASUMI-1 cells at 340 μM, and 60.93 ± 2.63% in NOMO-1 cells at 340 μM after 48 h treatment.
Caused a dose-dependent increase in Annexin V+ cells in KASUMI-1 cells at 48 h.
Confirmed apoptosis in MOLM-13 and KASUMI-1 cells via mitochondrial depolarization, DNA fragmentation, and caspase-3 activation.

Cell Cycle Analysis[1]

Cell Line: TP53-wild-type OCI-AML3, MOLM-13, and TP53-mutant KASUMI-1, NOMO-1 acute myeloid leukemia (AML) cell lines
Concentration: 85, 170, 340 μM
Incubation Time: 24 h; 48 h
Result: Caused no cell cycle alterations in MOLM-13 and KASUMI-1 cells at any tested concentration or time point.
Induced accumulation in the G0/G1 phase and a decrease in S phase cells after 24 and 48 h of treatment at all tested concentrations in NOMO-1 and OCI-AML3 cells.
Increased G2/M phase cells after treatment in OCI-AML3 cells.
Clinical Trial
Molecular Weight

143.21

Formula

C5H9N3S
CAS No.
SMILES

N#CCCCSC(=N)N
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Kevetrin Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Kevetrin500863-50-33-Cyanopropyl carbamimidothioate 4-IsothioureidobutyronitrileApoptosisMDM-2/p53cell growth arrestRb-E2F tumor suppressor pathwayHsp90TP53-mutant acute myeloid leukemia cellsacute myeloid leukemiaapoptosisHDAC6p53E2F1MDM2Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Kevetrin
Cat. No.:
HY-16270
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.